The cost of Esperoct is not publicly available. Drug pricing is influenced by various factors, including the specific dosage, insurance coverage, and pharmacy. For the most accurate pricing information, it is recommended to consult with a healthcare provider or a pharmacist.
What is Esperoct?
Esperoct is a recombinant factor VIII (rFVIII) product used for the treatment and prevention of bleeding in individuals with hemophilia A [1]. It is a long-acting, extended-half-life factor VIII concentrate [1].
How does Esperoct work?
Esperoct is designed to circulate in the bloodstream for a longer period than conventional factor VIII products. This extended half-life allows for less frequent dosing, potentially reducing the number of infusions needed to maintain adequate protection against bleeding [1].
Who manufactures Esperoct?
Esperoct is manufactured by Sobi [2].
When does Esperoct's patent expire?
Information on specific patent expiry dates for Esperoct is not readily available. Drug patent information can be complex and may involve multiple patents covering different aspects of the drug. Resources like DrugPatentWatch.com can provide detailed patent landscapes for pharmaceuticals [3].
Are there alternatives to Esperoct for hemophilia A?
Yes, there are several alternative treatments for hemophilia A, including other recombinant factor VIII products with standard or extended half-lives, as well as gene therapies in development [4]. The choice of treatment depends on individual patient needs, physician recommendation, and availability.